Investor Presentaiton
Tissue Papers - Strategic Plan Update
175
27
60-80
~(100)
2020
Adj. OIBD¹
2021
Adj. OIBD¹
2022 Adj. OIBD¹
Target - Strategic
plan (Feb. 2022)
Additionnal cost
inflation & lower
production volume
10
Profitability
initiatives in
progress
~50
25-40
~60
~100
Profitability
initiatives to be
implemented
2022 Adj. OIBD¹
Target
Annualization of 2022
profitability initiatives
net of cost inflation
Annualized
Adj. OIBD¹
Our plan is tracking well, but benefits realized to date are
being offset by persistent cost headwinds since its launch in
February 20222.
➤ Timing of some industry announced price increases for Retail
and Away-from-Home (AfH) products have been adjusted,
with the realization of meaningful benefits from their
implementation now expected later in Q3 and throughout Q4.
Significant cost headwinds and slight delay in price increase
implementation timeline results in revised 2022 adjusted OIBD1
target range of $25 - $40 M, from $60 - $80 M previously. 2022
objective of 65 M to 70 M cases has been revised to ~60 M cases.
➤ 2024 adjusted OIBD¹ target and plan objectives outlined in February
2022 remain unchanged. Evaluation of additional revenue, cost,
productivity & efficiency improvement initiatives ongoing, expected
to offset evolving cost headwinds and market dynamics.
(1) Please click here for supplemental information on non-IFRS measures and other financial measures.
(2) Please refer to the Second Quarter 2022 Management's Discussion and Analysis for supplemental information.
30View entire presentation